# Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

> **NCT00734565** · PHASE1 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 40 (actual)

## Conditions studied

- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** Haemophilus influenzae type b

## Key facts

- **NCT ID:** NCT00734565
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2012-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734565, "Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00734565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*